Abstracts tagged "pharmacotherapy"

Abstract Number: 090 • 2023 Pediatric Rheumatology Symposium
Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience
Angela Chun¹, MaiLan Nguyen¹, Marietta De Guzman² and Andrea Ramirez³, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: The management of pediatric rheumatic disease has been forever changed by the advent of biologic drugs and the pursuit of targeted therapy. There is…
Abstract Number: 1772 • 2019 ACR/ARP Annual Meeting
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Arisa Yaekura¹, Kanta Morii ², Yuto Oketani ³, Ikumi Okumura ², Kenta Kaneshiro ⁴, Kohsuke Yoshida ², Yoshiko Kawasaki ⁵, Nao Shibanuma ⁵, Yoshitada Sakai ⁶ and Akira Hashiramoto ², ¹Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ³Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, ⁵Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁶Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of…
Abstract Number: 2399 • 2019 ACR/ARP Annual Meeting
Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis
Carlos Sánchez-Piedra¹, María Colazo ², Rosa Roselló ³, Cristina Campos ⁴, P. Vela ⁵, Cristina Bohorquez ⁶, Carolina Pérez-García ⁷, Manuel Pombo-Suarez ⁸, Carlos Fernández-López ⁹, Dolores Ruiz-Montesinos ¹⁰, Fernando Alonso ¹¹, Federico Diaz-Gonzalez ¹² and Juan Jesús Gómez-Reino ¹³, ¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²Hospital de Burgos, Burgos, ³Hospital San Jorge, Huesca, ⁴Hospital General de Valencia, Valencia, ⁵Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ⁶Universitary Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcala de Henares, Spain, ⁷Rheumatology, Hospital del Mar, Barcelona, Catalonia, Spain, ⁸Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ¹⁰Hospital Virgen Macarena, Sevilla, ¹¹Unidad Investigación SER, Madrid, Spain, ¹²Hospital de Canarias, Tenerife, ¹³Hospital de Santiago, Santiago de Compostela
Background/Purpose: During the past 15 years, advancements in the understanding of the safety and effectiveness, as well as the expanding access and availability of biologic…
Abstract Number: 2580 • 2019 ACR/ARP Annual Meeting
Pharmacotherapies Targeting Type 2 SLE Symptoms
Raeann Whitney¹, Amanda Eudy ¹, Megan Clowse ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, David Pisetsky ², Kai Sun ¹, Rebecca Sadun ¹ and Jennifer Rogers ¹, ¹Duke University, Durham, ²Duke University, Durham VAMC, Durham
Background/Purpose: We propose categorizing lupus activity to better align with patient experience: Type 1 SLE activity includes classic symptoms such as arthritis and nephritis; Type…
Abstract Number: 1166 • 2017 ACR/ARHP Annual Meeting
Systemic Degos Disease: Long Term Survival on Combined Therapy with Eculizumab and Treprostinil
Lee S. Shapiro^1,2, Jessica Farrell^1,2,3, Roberta Lukasiewicz^1,2, Peter A. Merkel⁴, Douglas Rosing⁵, Manfred Boehm⁶, Axia Toledo-Garcia¹, Maria Karas⁷, Maria DeSancho⁸, Harry McCoy⁹, Michael Marmulstein¹⁰ and Scott Beegle¹¹, ¹The Center for Rheumatology, Albany, NY, ²Steffens Scleroderma Center, Albany, NY, ³Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, ⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, MN, ⁵Cardiovascular Pulmonary Branch, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, ⁶Center for Molecular Medicine, NHLBI/ NIH, Bethesda, MD, ⁷Division of Cardiology/Department of Medicine,, Weill Cornell Medical College, New York, NY, ⁸Weill Cornell Medical Center, New York, NY, ⁹Blue Ridge Cancer Care, Blacksburg, VA, ¹⁰Albany Associates in Cardiology, Albany, NY, ¹¹Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, NY
Background/Purpose: Degos disease (Malignant Atrophic Papulosis) is a thrombotic microvasculopathy of complement activation, endothelial cell injury and progressive microvascular obliteration. Lesions are marked by vascular…
Abstract Number: 2206 • 2016 ACR/ARHP Annual Meeting
Data on Treatment from Brazilian Fibromyalgia Patients Registry (EpiFibro)
José E. Martinez^1,2, Marcelo C. Rezende^1,3, Eduardo Paiva^1,4, Daniel Pollak^1,5, Milton Helfenstein Jr^1,6, Jose Roberto Provenza^1,7, Aline Ranzolin^1,8, Luiz Severiano Ribeiro^1,9, Eduardo J. R. Souza^1,10, Roberto E Heymann^1,11 and Marcos Renato Assis^1,12, ¹Brazilian Society of Rheumatology, São Paulo, Brazil, ²Rheumatology, Pontificia Universidade Católica de São Paulo, Sorocaba, Brazil, ³Santa Casa de Campo Grande, Campo Grande, Brazil, ⁴Rheumatology, Universidade Federal do Parana, Curitiba Parana, Brazil, ⁵Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ⁶RUA JOAO DE LACERDA SOARES, 90, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁷Rheumatology, Pontifícia Universidade Católica de Campinas, Campinas, Brazil, ⁸Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, ⁹Instituto de Previdência dos Servidores do Estado de Minas Gerais, Belo Horizonte, Brazil, ¹⁰Santa Casa de Belo Horizonte, Belo Horizonte, Brazil, ¹¹Universidade Federal de São Paulo, São Paulo, Brazil, ¹²Rheumatology, Faculdade de Medicina de Marilia, Marilia, Brazil
Background/Purpose: The Brazilian registry on fibromyalgia syndrome (EpiFibro) included 810 patients who satisfied the American College of Rheumatology Classification Criteria for Fibromyalgia (ACR1990) at the…
Abstract Number: 3152 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA): Premature Use of Biologics Accelerating in United States (US)
James R. O'Dell¹, Stanley B. Cohen², J Carter Thorne³ and Ted R Mikuls⁴, ¹Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Metroplex Clinical Research Center, Dallas, TX, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The treatment of RA has changed dramatically in the past several decades with the advent of a large number of new biologic agents as…
Abstract Number: 1492 • 2015 ACR/ARHP Annual Meeting
Implementation in Clinical Practice of a Medication Assessment Tool Specific for Rheumatoid Arthritis, Rhmat
Louise Grech^1,2, Anthony Serracino Inglott¹, Victor Ferrito¹ and Lilian M. Azzopardi¹, ¹Department of Pharmacy, University of Malta, Msida, Malta, ²Clinical Pharmacy Practice Unit, Department of Pharmacy, Mater Dei Hospital, Msida, Malta
Background/Purpose: The RhMAT is a medication assessment tool developed to specifically analyse pharmacotherapy adherence to evidence based medicine and guidelines on the management of rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].